The optimization of standard therapy, novel drug combinations, and new targets for Waldenstrom’s macroglobulinemia are generating excitement, said Stephen Ansell, MD, PhD, from the Mayo Clinic in Rochester, Minnesota.After the approval of ibrutinib (Imbruvica, Pharmacyclics and Janssen) for Waldenstrom’s macroglobulinemia in 2015, investigators began looking at other Bruton’s tyrosine kinase (BTK) inhibitors to determine which...
